2022
Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study
Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2022, 77: 489-500. PMID: 35984731, PMCID: PMC9877112, DOI: 10.1002/hep.32737.Peer-Reviewed Original ResearchConceptsNonselective beta blockersSelective beta blockersLiver-related mortalityHepatic decompensationBeta blockersCTP classPlatelet countSubgroup analysisLiver disease etiologyLower hazardNational cohort studyNew-user designInverse probability treatmentRoutine clinical settingPrior decompensationViremia statusChild-TurcotteHCV viremiaClinical confoundersComposite outcomeCohort studyPrimary outcomeActive comparatorNational cohortDecompensation
2012
Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer?
Guevara M, Groszmann R, Iwakiri Y, Taddei T. Beta‐blockers in patients with refractory ascites: To treat or not to treat. That is the question? But, what is the answer? Hepatology 2012, 56: 384-386. PMID: 22454325, DOI: 10.1002/hep.25724.Peer-Reviewed Original ResearchParacentesis-induced circulatory dysfunctionIncidence of paracentesis-induced circulatory dysfunctionPlasma renin concentrationRefractory ascitesBeta-blockersArterial pressureDevelopment of paracentesis-induced circulatory dysfunctionHeart rateTreated with beta-blockersChild-Pugh C.Intravenous albumin administrationBeta-blocker therapyEradication of varicesCross-over studyBaseline 1 weekEndoscopic eradicationAlbumin administrationBeta blockersMELD scoreRenin concentrationCirculatory dysfunctionAscitesCirrhosisParacentesisPatients